Expression of Plasma miRNA-133a is Significantly Lower in Acute Coronary Syndrome (ACS) than in Healthy/Non-ACS Subjects
Journal: The Indonesian Biomedical Journal (Vol.16, No. 5)Publication Date: 2024-10-01
Authors : Ermin Rachmawati; Djanggan Sargowo; Indra Wahyu Saputra; Riskiyah Riskiyah; Ikhwan Handirosiyanto; Arief Rachman Hakim; Mahrus Ismail; Tarsadi Tarsadi; Syafiq Maulana; Iwal Reza Ahdi; Alvina Puspitasari; Syanindita Puspa Wardhani;
Page : 464-72
Keywords : circulating miRNA; miRNA-133a; acute coronary syndrome; diagnostic biomarker;
Abstract
BACKGROUND: The current biomarker diagnostic modality for acute coronary syndrome (ACS), cardiac troponin, has several limitations. Emerging studies showed that micro-RNA (miR)-133a was released from infarcted heart to circulation, yet the diagnostic value of miR-133a in ACS demonstrated a conflicting result. Therefore, this study was conducted to investigate the potency of plasma miR-133a as a biomarker candidate of ACS. METHODS: This was a case-controlled study, involving ACS and control subjects. The sociodemographic and clinical characteristics were assessed through medical records. A final of 39 ACS and 31 control subjects (consist of healthy and non-ACS subjects) passed the selection procedure by demonstrating a high purity of RNA. miR-133a from ACS and control subjects were detected by quantitative polymerase chain reaction (qPCR). Expression of miR-133a was evaluated for sensitivity and specificity as an ACS biomarker diagnostic using the receiver operating characteristic (ROC) curve. RESULTS: Plasma miR-133a expression was stably found in ACS subjects. The plasma miR-133a level was lower in ACS than in control subjects. miR-133a effectively distinguished ACS subjects from healthy subjects (AUC=0.911) and exhibited high diagnostic performance, with a sensitivity of 87.1% and specificity of 100% at a cut-off value of 44.035. In an extended model including both control subjects (healthy and non-ACS with comorbid conditions), miR-133a maintained diagnostic significance (AUC=0.874), showing sensitivity of 76.9% and specificity of 100% at a cut-off value of 11.69. CONCLUSION: Plasma miR-133a is significantly lower and effectively distinguishes ACS patients from both healthy individuals and non-ACS individuals with comorbid, with a cut-off value of 11.69. Therefore, plasma miR-133a is suggested to be a good candidate for diagnostic biomarkers of ACS.
Other Latest Articles
- Black Rice Extract Reduces Body Weight, Waist Circumference, Body Mass Index and Lipopolysaccharide in Obese Subjects: A Preliminary Study
- Propofol and Nigella sativa L Seeds Ethanol Extract Enhance Neuroprotection: A Histopathological Study in Rat Models with Traumatic Brain Injury
- Diabetes Risk Allele of Transcription Factor 7-like 2 (TCF7L2) Polymorphisms is Associated with Higher Glucagon-like Peptide 1 (GLP1) and Lower Insulin Secretion
- Adiponectin and Endothelin-1 are Correlated with the Development of Normal-tension Glaucoma in Metabolic Syndrome Patients
- Luteolin Suppresses Endothelial Permeability and Nitric Oxide Scavenging Effects
Last modified: 2024-11-01 18:26:47